NCT07163182View on ClinicalTrials.gov

Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and Removed in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 11, 2026

Study Completion Date

August 11, 2026

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

CHF6467 Part 1 (SAD)

Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts

BIOLOGICAL

CHF6467 Part 2 (MAD)

Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts

DRUG

Placebo

Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2

Trial Locations (1)

1618

RECRUITING

Bulgaria MC Comac Medical Ltd., Sofia

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY